<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228718</url>
  </required_header>
  <id_info>
    <org_study_id>09.2019.728</org_study_id>
    <nct_id>NCT04228718</nct_id>
  </id_info>
  <brief_title>The Burden of Primary Caregivers of Spinal Muscular Atrophy Patients and Their Needs</brief_title>
  <official_title>The Burden of Primary Caregivers of Spinal Muscular Atrophy Patients and Their Needs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marmara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess carer burden, needs, and expectations of Spinal
      Muscular Atrophy Parents
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spinal muscular atrophy (SMA) is a group of neuromuscular diseases involving the spinal cord
      anterior horn cells and brain stem motor nuclei. It is followed by programmed cell death. It
      progresses with symmetrical weakness and atrophy of voluntary muscles throughout the body. It
      leads to a decrease in mobility with progressive loss of power, and pulmonary function
      impairment with the involvement of the respiratory muscles.

      Families who are confronted with these problems that arise after the birth of the baby or
      shortly after birth have a serious adaptation problem. When the course of the disease and its
      incurability are explained, patients and their families are under severe stress. Physical and
      emotional health is worse than normal healthy growing children's parents.

      They need information, psychological and social support. The role of the family is very
      important in the life of children with disabilities. Family-oriented care; has been developed
      to facilitate the care process of children with special needs and to help their families. The
      main characteristics of the family-oriented approach are that families know their children in
      the best way, that each family is unique and different, and that family and community support
      is provided for the child's functionality. The assessment of family function helps the
      planning and management of treatment according to the concerns of the family. The education
      of the family, the socio-cultural structure and the psychological approach of the parents
      play an important role in the development of the child with SMA.

      The aim of this study was to evaluate the care burden, needs and expectations of SMA parents
      and to reveal the problems clearly; so that this information can be used in rehabilitation
      planning and interpretation of results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Zarit Burden Interview Scale</measure>
    <time_frame>Day 0</time_frame>
    <description>It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Family Needs Survey (FNS)</measure>
    <time_frame>Day 0</time_frame>
    <description>It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)</measure>
    <time_frame>Day 0</time_frame>
    <description>CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hammersmith Functional Motor Scale Expanded (HMFSE)</measure>
    <time_frame>Day 0</time_frame>
    <description>It is an extended version of the 20-item HFMS. Based on another scale known as Gross Motor Function Measure, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.</description>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Spinal Muscular Atrophy</condition>
  <condition>Caregiver Burden</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Zarit Burden Interview Scale</intervention_name>
    <description>It is a questionnaire consisting of 22 items. A minimum score of 0 and a maximum score of 88 can be obtained. The higher the scale score, the higher the difficulty experienced.</description>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Family Needs Survey (FNS)</intervention_name>
    <description>It is a questionnaire consisting of 35 items prepared to determine the requirements. In the FNS survey; The points given to the items can be directly collected and the amount of family needs can be determined over the total score. The lowest score that can be obtained from FNS is 29 and the highest score is 87. As the scores obtained from the scale and subscales increase, it can be said that the families' level of necessity increases.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)</intervention_name>
    <description>CHOP-INTEND uses a scale of 0-64 points. Higher scores indicate better motor function. It is used to reliably measure natural motor function decline in infants with SMA Type 1.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hammersmith Functional Motor Scale Expanded (HMFSE)</intervention_name>
    <description>It is an extended version of the 20-item HFMS. Based on another scale known as GMFM, 13 items were added and expanded HFMS to include these elements. Therefore, HFMSE is a scale used to evaluate motor functions in types 2 and 3 SMA. It contains 33 items with a total score of 66 on a scale of 0, 1, 2.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with SMA type 1, type 2 or type 3 between the ages of 0-18 and their caregivers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with spinal muscular atrophy at between the ages of 0-18

          2. Agree to participate in the study

        Exclusion Criteria:

        1-Refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naime Evrim Karadag Saygi, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Department of PM&amp;R, Marmara University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayca Evkaya, Res. Asst.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Physiotherapy and Rehabilitation, Maltepe University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marmara University School of Medicine Department of Physical Medicine and Rehabilitation</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Flunt D, Andreadis N, Menadue C, Welsh AW. Clinical commentary: obstetric and respiratory management of pregnancy with severe spinal muscular atrophy. Obstet Gynecol Int. 2009;2009:942301. doi: 10.1155/2009/942301. Epub 2009 May 19.</citation>
    <PMID>19960049</PMID>
  </reference>
  <reference>
    <citation>Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet. 1978 Dec;15(6):409-13.</citation>
    <PMID>745211</PMID>
  </reference>
  <reference>
    <citation>Strober JB, Tennekoon GI. Progressive spinal muscular atrophies. J Child Neurol. 1999 Nov;14(11):691-5. Review.</citation>
    <PMID>10593543</PMID>
  </reference>
  <reference>
    <citation>Wirth B, Brichta L, Schrank B, Lochm√ºller H, Blick S, Baasner A, Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006 May;119(4):422-8. Epub 2006 Mar 1.</citation>
    <PMID>16508748</PMID>
  </reference>
  <reference>
    <citation>Ho HM, Tseng YH, Hsin YM, Chou FH, Lin WT. Living with illness and self-transcendence: the lived experience of patients with spinal muscular atrophy. J Adv Nurs. 2016 Nov;72(11):2695-2705. doi: 10.1111/jan.13042. Epub 2016 Jun 30.</citation>
    <PMID>27293032</PMID>
  </reference>
  <reference>
    <citation>Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, Kang PB, Foley AR, Yang ML, Martens WB, Oskoui M, Glanzman AM, Flickinger J, Montes J, Dunaway S, O'Hagen J, Quigley J, Riley S, Benton M, Ryan PA, Montgomery M, Marra J, Gooch C, De Vivo DC. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014 Aug 26;83(9):810-7. doi: 10.1212/WNL.0000000000000741. Epub 2014 Jul 30.</citation>
    <PMID>25080519</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Muscular Atrophy</keyword>
  <keyword>Caregiver Burden</keyword>
  <keyword>Disabled persons</keyword>
  <keyword>Caregivers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

